JP2018533954A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533954A5 JP2018533954A5 JP2018524194A JP2018524194A JP2018533954A5 JP 2018533954 A5 JP2018533954 A5 JP 2018533954A5 JP 2018524194 A JP2018524194 A JP 2018524194A JP 2018524194 A JP2018524194 A JP 2018524194A JP 2018533954 A5 JP2018533954 A5 JP 2018533954A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- expression
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15194367 | 2015-11-12 | ||
| EP15194367.7 | 2015-11-12 | ||
| EP16189502.4 | 2016-09-19 | ||
| EP16189502 | 2016-09-19 | ||
| PCT/EP2016/077383 WO2017081223A1 (en) | 2015-11-12 | 2016-11-11 | Oligonucleotides for inducing paternal ube3a expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020136397A Division JP7279000B2 (ja) | 2015-11-12 | 2020-08-12 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533954A JP2018533954A (ja) | 2018-11-22 |
| JP2018533954A5 true JP2018533954A5 (https=) | 2020-04-09 |
| JP6751142B2 JP6751142B2 (ja) | 2020-09-02 |
Family
ID=57345910
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521350A Pending JP2018533362A (ja) | 2015-11-12 | 2016-11-11 | 薬物候補の有効性プロファイルを決定するための方法 |
| JP2018521433A Expired - Fee Related JP7066609B2 (ja) | 2015-11-12 | 2016-11-11 | 霊長類種に由来する標準化された神経細胞アッセイ |
| JP2018524194A Active JP6751142B2 (ja) | 2015-11-12 | 2016-11-11 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2020136397A Active JP7279000B2 (ja) | 2015-11-12 | 2020-08-12 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2021113496A Pending JP2021191262A (ja) | 2015-11-12 | 2021-07-08 | 薬物候補の有効性プロファイルを決定するための方法 |
| JP2023009553A Pending JP2023052630A (ja) | 2015-11-12 | 2023-01-25 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2024196762A Pending JP2025024060A (ja) | 2015-11-12 | 2024-11-11 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521350A Pending JP2018533362A (ja) | 2015-11-12 | 2016-11-11 | 薬物候補の有効性プロファイルを決定するための方法 |
| JP2018521433A Expired - Fee Related JP7066609B2 (ja) | 2015-11-12 | 2016-11-11 | 霊長類種に由来する標準化された神経細胞アッセイ |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020136397A Active JP7279000B2 (ja) | 2015-11-12 | 2020-08-12 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2021113496A Pending JP2021191262A (ja) | 2015-11-12 | 2021-07-08 | 薬物候補の有効性プロファイルを決定するための方法 |
| JP2023009553A Pending JP2023052630A (ja) | 2015-11-12 | 2023-01-25 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2024196762A Pending JP2025024060A (ja) | 2015-11-12 | 2024-11-11 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
Country Status (30)
| Country | Link |
|---|---|
| US (10) | US10494633B2 (https=) |
| EP (5) | EP3374499A1 (https=) |
| JP (7) | JP2018533362A (https=) |
| KR (4) | KR102840652B1 (https=) |
| CN (5) | CN108350432A (https=) |
| AU (4) | AU2016352836B2 (https=) |
| CA (1) | CA3004799C (https=) |
| CL (3) | CL2018001189A1 (https=) |
| CO (1) | CO2018004550A2 (https=) |
| CR (3) | CR20200118A (https=) |
| DK (2) | DK3374509T3 (https=) |
| ES (2) | ES2852998T4 (https=) |
| FI (1) | FI4220360T3 (https=) |
| HK (2) | HK1258434A1 (https=) |
| HR (2) | HRP20241138T1 (https=) |
| HU (2) | HUE067905T2 (https=) |
| IL (4) | IL300119B1 (https=) |
| LT (2) | LT3374509T (https=) |
| MA (1) | MA67580B1 (https=) |
| MX (4) | MX2018004978A (https=) |
| PE (2) | PE20210451A1 (https=) |
| PH (1) | PH12018501005A1 (https=) |
| PL (2) | PL3374509T3 (https=) |
| RS (2) | RS61529B9 (https=) |
| RU (1) | RU2742007C2 (https=) |
| SG (1) | SG11201803951QA (https=) |
| SI (2) | SI3374509T1 (https=) |
| UA (1) | UA125963C2 (https=) |
| WO (3) | WO2017081223A1 (https=) |
| ZA (1) | ZA201802494B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2572826C2 (ru) | 2008-12-02 | 2016-01-20 | Чиралджен, Лтд. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| CA2767253A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Novel nucleic acid prodrugs and methods of use thereof |
| EP3626823A1 (en) | 2009-09-11 | 2020-03-25 | Ionis Pharmaceuticals, Inc. | Modulation of huntingtin expression |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| AU2012284265B2 (en) | 2011-07-19 | 2017-08-17 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| ES2809199T3 (es) | 2012-06-25 | 2021-03-03 | Ionis Pharmaceuticals Inc | Modulación de la expresión de UBE3A-ATS |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| JP6453212B2 (ja) | 2012-07-13 | 2019-01-16 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | キラル制御 |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| WO2016086104A1 (en) | 2014-11-25 | 2016-06-02 | Ionis Pharmaceuticals, Inc. | Modulation of ube3a-ats expression |
| HUE067905T2 (hu) | 2015-11-12 | 2024-11-28 | Hoffmann La Roche | Oligonukleotidok paternális UBE3A expresszió indukálására |
| PT3717646T (pt) | 2017-12-01 | 2025-07-28 | Texas A & M Univ Sys | Tratamento antisense da síndrome de angelman |
| AU2019218987B2 (en) | 2018-02-12 | 2025-04-24 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| CN108795935B (zh) * | 2018-05-23 | 2022-06-21 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 日本血吸虫SjELAV-like 1基因的siRNA及其应用 |
| CA3113648A1 (en) | 2018-09-21 | 2020-03-26 | University Of Connecticut | Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome |
| JP7241185B2 (ja) * | 2019-01-17 | 2023-03-16 | エフ． ホフマン－ラ ロシュ アーゲー | Ｅ３ユビキチンリガーゼ（ｕｂｅ３ａ）のタンパク質標的 |
| CA3130431A1 (en) * | 2019-02-20 | 2020-08-27 | Roche Innovation Center Copenhagen A/S | Phosphonoacetate gapmer oligonucleotides |
| FI3947684T3 (fi) * | 2019-03-29 | 2025-05-27 | Ionis Pharmaceuticals Inc | Yhdisteitä ja menetelmiä ube3a-ats:n moduloimiseksi |
| WO2020237130A1 (en) * | 2019-05-22 | 2020-11-26 | The University Of North Carolina At Chapel Hill | Ube3a genes and expression cassettes and their use |
| JP7701879B2 (ja) | 2019-05-28 | 2025-07-02 | エフ． ホフマン－ラ ロシュ アーゲー | 単球前駆細胞を生成するための方法 |
| TW202204607A (zh) * | 2020-04-16 | 2022-02-01 | 英商羅斯林科技有限公司 | 誘導性多功能幹細胞(iPSC)之誘導 |
| US20230212572A1 (en) * | 2020-06-09 | 2023-07-06 | Roche Innovation Center Copenhagen A/S | Guanosine Analogues for Use in Therapeutics Polynucleotides |
| JPWO2022158487A1 (https=) | 2021-01-21 | 2022-07-28 | ||
| CN119173632A (zh) | 2022-05-10 | 2024-12-20 | 豪夫迈·罗氏有限公司 | 靶向cfp-elk1基因间区域的反义寡核苷酸 |
| CN121263524A (zh) | 2023-05-04 | 2026-01-02 | 豪夫迈·罗氏有限公司 | 能够上调葡糖脑苷脂酶表达的寡核苷酸 |
| KR20250068540A (ko) * | 2023-11-08 | 2025-05-16 | 한국과학기술원 | Ube3a를 표적으로 하여 발현증강을 유도하는 안티센스 올리고뉴클레오티드 및 이의 용도 |
| WO2025125542A1 (en) | 2023-12-15 | 2025-06-19 | F. Hoffmann-La Roche Ag | Intrathecal dosage method |
| WO2025213123A1 (en) * | 2024-04-05 | 2025-10-09 | Encoded Therapeutics, Inc. | Methods and compositions for increasing expression of ube3a |
| TW202548015A (zh) * | 2024-04-11 | 2025-12-16 | 美商奧崔基尼克斯製藥公司 | 天使症候群反義治療的給藥方案 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4373084A (en) | 1981-07-07 | 1983-02-08 | E. I. Du Pont De Nemours And Company | Sulfur-modified polypropylene ether glycols, a method for preparing them, and polyurethanes prepared therefrom |
| WO1993007883A1 (en) | 1991-10-24 | 1993-04-29 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6617162B2 (en) | 2001-12-18 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of estrogen receptor alpha expression |
| AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
| US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| AU1853600A (en) * | 1999-01-06 | 2000-07-24 | Choong-Chin Liew | Method for the detection of gene transcripts in blood and uses thereof |
| CZ296576B6 (cs) | 1999-02-12 | 2006-04-12 | Sankyo Company Limited | Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem |
| EP1178999B1 (en) | 1999-05-04 | 2007-03-14 | Santaris Pharma A/S | L-ribo-lna analogues |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| CA2396460A1 (en) | 1999-12-02 | 2001-06-07 | Myriad Genetics, Inc. | Protein-protein interactions |
| US6300132B1 (en) | 1999-12-17 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Antisense inhibition of telomeric repeat binding factor 2 expression |
| AU2001268163A1 (en) * | 2000-06-01 | 2001-12-11 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ube3a gene |
| US20030087855A1 (en) | 2001-09-13 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of protein kinase R expression |
| CA2790034A1 (en) * | 2001-06-21 | 2003-01-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
| US20050124572A1 (en) * | 2002-06-17 | 2005-06-09 | Freier Susan M. | Compositions and their uses directed to signal tranducers |
| AU2003268096A1 (en) | 2002-08-14 | 2004-03-03 | Pharmacia Corporation | ANTISENSE MODULATION OF Nav1.3 EXPRESSION |
| AU2003270900A1 (en) * | 2002-09-25 | 2004-04-19 | Pharmacia Corporation | Antisense modulation of microsomal prostaglandin e2 synthase expression |
| US9045518B2 (en) | 2002-11-18 | 2015-06-02 | Santaris Pharma A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
| EP1670901A4 (en) * | 2003-08-29 | 2007-09-05 | Wisconsin Alumni Res Found | METHOD FOR IN VITRO DIFFERENTIATION OF NEURAL STEM CELLS, MOTOR NEURONES AND DOPAMINE NEURONES FROM EMBRYONAL PRIMATIVE STEM CELLS |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| US8288354B2 (en) | 2005-12-28 | 2012-10-16 | The Scripps Research Institute | Natural antisense and non-coding RNA transcripts as drug targets |
| JP5342881B2 (ja) | 2006-01-27 | 2013-11-13 | アイシス ファーマシューティカルズ， インコーポレーテッド | ６−修飾された二環式核酸類似体 |
| EP2023940B1 (en) | 2006-05-05 | 2011-06-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of sglt2 |
| AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| WO2008113832A2 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
| PE20090064A1 (es) | 2007-03-26 | 2009-03-02 | Novartis Ag | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende |
| EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| CA2692579C (en) | 2007-07-05 | 2016-05-03 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
| WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
| DK2285819T3 (da) | 2008-04-04 | 2013-12-02 | Isis Pharmaceuticals Inc | Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| US8642334B2 (en) * | 2009-02-17 | 2014-02-04 | Memorial Sloan Kettering Cancer Center | Methods of neural conversion of human embryonic stem cells |
| EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| JP5843775B2 (ja) * | 2009-10-13 | 2016-01-13 | ステムセル テクノロジーズ インコーポレーティッド | 幹細胞を分化させるための重量オスモル濃度の操作法 |
| NO2516648T3 (https=) | 2009-12-23 | 2018-04-07 | ||
| EP2580228B1 (en) | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| CN103068982B (zh) | 2010-07-14 | 2017-06-09 | 库尔纳公司 | 通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病 |
| WO2012012467A2 (en) | 2010-07-19 | 2012-01-26 | Isis Pharmaceuticals, Inc. | Modulation of nuclear-retained rna |
| BR112013003031A2 (pt) * | 2010-08-19 | 2016-06-14 | Hoffmann La Roche | método de produção de células hastes neurais (chn), células hastes neurais e seu uso, composição terapêutica e banco biológico de nscs |
| WO2012064806A2 (en) | 2010-11-11 | 2012-05-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for unsilencing imprinted genes |
| CA3077910A1 (en) | 2010-11-17 | 2012-05-24 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| JP6185907B2 (ja) * | 2011-03-30 | 2017-08-23 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 神経分化のための多能性幹細胞の予備刺激 |
| US20120282176A1 (en) | 2011-04-20 | 2012-11-08 | Roche Glycart Ag | Method and Constructs for the pH Dependent Passage of the Blood-brain-barrier |
| EP3453761A1 (en) | 2011-08-29 | 2019-03-13 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| CN104136451A (zh) | 2011-09-07 | 2014-11-05 | 玛瑞纳生物技术有限公司 | 具有构象限制的单体的核酸化合物的合成和用途 |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| ES2809199T3 (es) * | 2012-06-25 | 2021-03-03 | Ionis Pharmaceuticals Inc | Modulación de la expresión de UBE3A-ATS |
| US10077443B2 (en) | 2012-11-15 | 2018-09-18 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
| WO2014077693A1 (en) | 2012-11-16 | 2014-05-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for reducing an effect of aging in a mammalian cell |
| WO2015143342A1 (en) * | 2014-03-21 | 2015-09-24 | Cellular Dynamics International, Inc. | Production of midbrain dopaminergic neurons and methods for the use thereof |
| HUE067905T2 (hu) | 2015-11-12 | 2024-11-28 | Hoffmann La Roche | Oligonukleotidok paternális UBE3A expresszió indukálására |
| EP3645012A4 (en) | 2017-06-28 | 2021-06-30 | University Of South Florida | MODIFIED UBE3A GENE FOR A GENE THERAPY APPROACH FOR ANGELMAN SYNDROME |
| PT3717646T (pt) | 2017-12-01 | 2025-07-28 | Texas A & M Univ Sys | Tratamento antisense da síndrome de angelman |
| EP3743116B1 (en) | 2018-01-26 | 2024-07-10 | F. Hoffmann-La Roche AG | Radiolabelled oligonucleotides and process for their preparation |
| FI3947684T3 (fi) | 2019-03-29 | 2025-05-27 | Ionis Pharmaceuticals Inc | Yhdisteitä ja menetelmiä ube3a-ats:n moduloimiseksi |
-
2016
- 2016-11-11 HU HUE23152543A patent/HUE067905T2/hu unknown
- 2016-11-11 LT LTEP16798440.0T patent/LT3374509T/lt unknown
- 2016-11-11 HR HRP20241138TT patent/HRP20241138T1/hr unknown
- 2016-11-11 CN CN201680066009.XA patent/CN108350432A/zh active Pending
- 2016-11-11 WO PCT/EP2016/077383 patent/WO2017081223A1/en not_active Ceased
- 2016-11-11 DK DK16798440.0T patent/DK3374509T3/da active
- 2016-11-11 CN CN201680065987.2A patent/CN108350431A/zh active Pending
- 2016-11-11 UA UAA201806476A patent/UA125963C2/uk unknown
- 2016-11-11 HK HK19100670.6A patent/HK1258434A1/zh unknown
- 2016-11-11 EP EP16798672.8A patent/EP3374499A1/en not_active Withdrawn
- 2016-11-11 HU HUE16798440A patent/HUE053197T2/hu unknown
- 2016-11-11 IL IL300119A patent/IL300119B1/en unknown
- 2016-11-11 SG SG11201803951QA patent/SG11201803951QA/en unknown
- 2016-11-11 CN CN201680066253.6A patent/CN108291226B/zh active Active
- 2016-11-11 EP EP16797824.6A patent/EP3374498A1/en not_active Withdrawn
- 2016-11-11 LT LTEP23152543.7T patent/LT4220360T/lt unknown
- 2016-11-11 EP EP20204481.4A patent/EP3798307A1/en active Pending
- 2016-11-11 WO PCT/EP2016/077435 patent/WO2017081254A1/en not_active Ceased
- 2016-11-11 CR CR20200118A patent/CR20200118A/es unknown
- 2016-11-11 PE PE2020000810A patent/PE20210451A1/es unknown
- 2016-11-11 HK HK19100676.0A patent/HK1258309A1/zh unknown
- 2016-11-11 PL PL16798440T patent/PL3374509T3/pl unknown
- 2016-11-11 SI SI201631093T patent/SI3374509T1/sl unknown
- 2016-11-11 ES ES16798440T patent/ES2852998T4/es active Active
- 2016-11-11 RS RS20210241A patent/RS61529B9/sr unknown
- 2016-11-11 PL PL23152543.7T patent/PL4220360T3/pl unknown
- 2016-11-11 KR KR1020227045154A patent/KR102840652B1/ko active Active
- 2016-11-11 WO PCT/EP2016/077429 patent/WO2017081250A1/en not_active Ceased
- 2016-11-11 ES ES23152543T patent/ES2991800T3/es active Active
- 2016-11-11 IL IL281211A patent/IL281211B2/en unknown
- 2016-11-11 AU AU2016352836A patent/AU2016352836B2/en active Active
- 2016-11-11 KR KR1020257024980A patent/KR20250121139A/ko active Pending
- 2016-11-11 CR CR20180264A patent/CR20180264A/es unknown
- 2016-11-11 MA MA67580A patent/MA67580B1/fr unknown
- 2016-11-11 HR HRP20210227TT patent/HRP20210227T1/hr unknown
- 2016-11-11 RU RU2018119315A patent/RU2742007C2/ru active
- 2016-11-11 DK DK23152543.7T patent/DK4220360T3/da active
- 2016-11-11 EP EP23152543.7A patent/EP4220360B9/en active Active
- 2016-11-11 JP JP2018521350A patent/JP2018533362A/ja active Pending
- 2016-11-11 JP JP2018521433A patent/JP7066609B2/ja not_active Expired - Fee Related
- 2016-11-11 JP JP2018524194A patent/JP6751142B2/ja active Active
- 2016-11-11 KR KR1020207033999A patent/KR102482440B1/ko active Active
- 2016-11-11 MX MX2018004978A patent/MX2018004978A/es unknown
- 2016-11-11 EP EP16798440.0A patent/EP3374509B1/en active Active
- 2016-11-11 CA CA3004799A patent/CA3004799C/en active Active
- 2016-11-11 CN CN202211275954.4A patent/CN116064539A/zh active Pending
- 2016-11-11 RS RS20241003A patent/RS66036B1/sr unknown
- 2016-11-11 IL IL325248A patent/IL325248A/en unknown
- 2016-11-11 PE PE2018000752A patent/PE20181157A1/es unknown
- 2016-11-11 KR KR1020187013292A patent/KR102185465B1/ko active Active
- 2016-11-11 CR CR20220077A patent/CR20220077A/es unknown
- 2016-11-11 FI FIEP23152543.7T patent/FI4220360T3/fi active
- 2016-11-11 SI SI201631843T patent/SI4220360T1/sl unknown
- 2016-11-11 CN CN202211275978.XA patent/CN116064540A/zh active Pending
- 2016-11-14 US US15/351,113 patent/US10494633B2/en active Active
-
2018
- 2018-04-03 IL IL258488A patent/IL258488B/en active IP Right Grant
- 2018-04-16 ZA ZA2018/02494A patent/ZA201802494B/en unknown
- 2018-04-23 MX MX2022016377A patent/MX2022016377A/es unknown
- 2018-04-23 MX MX2022016381A patent/MX2022016381A/es unknown
- 2018-04-23 MX MX2022016376A patent/MX2022016376A/es unknown
- 2018-04-26 CO CONC2018/0004550A patent/CO2018004550A2/es unknown
- 2018-05-03 CL CL2018001189A patent/CL2018001189A1/es unknown
- 2018-05-08 PH PH12018501005A patent/PH12018501005A1/en unknown
- 2018-05-11 US US15/977,970 patent/US20190154664A1/en not_active Abandoned
- 2018-05-11 US US15/977,895 patent/US20190144824A1/en not_active Abandoned
-
2019
- 2019-04-18 US US16/388,714 patent/US10739332B2/en active Active
- 2019-10-24 US US16/663,024 patent/US10718753B2/en active Active
-
2020
- 2020-04-02 CL CL2020000889A patent/CL2020000889A1/es unknown
- 2020-05-29 AU AU2020203573A patent/AU2020203573B2/en active Active
- 2020-07-20 US US16/933,445 patent/US11320421B2/en active Active
- 2020-08-12 JP JP2020136397A patent/JP7279000B2/ja active Active
-
2021
- 2021-07-08 JP JP2021113496A patent/JP2021191262A/ja active Pending
- 2021-08-13 CL CL2021002159A patent/CL2021002159A1/es unknown
-
2022
- 2022-01-21 US US17/581,089 patent/US11852627B2/en active Active
- 2022-08-05 AU AU2022211910A patent/AU2022211910B2/en active Active
-
2023
- 2023-01-25 JP JP2023009553A patent/JP2023052630A/ja active Pending
- 2023-01-25 AU AU2023200410A patent/AU2023200410B2/en active Active
- 2023-02-22 US US18/172,707 patent/US12259380B2/en active Active
- 2023-10-20 US US18/491,513 patent/US12566172B2/en active Active
-
2024
- 2024-11-11 JP JP2024196762A patent/JP2025024060A/ja active Pending
-
2025
- 2025-07-02 US US19/258,035 patent/US12596118B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533954A5 (https=) | ||
| HRP20210227T1 (hr) | Oligonukleotidi za indukciju ekspresije paternalnog gena ube3a | |
| MX2023010958A (es) | Agentes de arn modificados con efecto reducido fuera de la diana. | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| MX2024005653A (es) | Agentes de acido ribonucleico (arn) de cadena doble modificados. | |
| WO2013074974A3 (en) | Modified rnai agents | |
| BR112013010525A2 (pt) | tratamento de hbv | |
| BR112015021470A2 (pt) | conjugado de polímero para administração de um agente bioativo | |
| JP2018530530A5 (https=) | ||
| BR112015025766A2 (pt) | derivado de nucleosídeo altamente ativo para o tratamento de hcv | |
| PE20210668A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales | |
| BR112014019584A8 (pt) | Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c | |
| MX2020005680A (es) | Tratamiento antisentido del sindrome de angelman. | |
| CL2013003105A1 (es) | Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer | |
| JP2016520310A5 (https=) | ||
| EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
| JP2021500016A5 (https=) | ||
| JP2011515357A5 (https=) | ||
| WO2013162350A3 (en) | Circular antiviral rna | |
| JP2011519365A5 (https=) | ||
| BR112018010736A2 (pt) | oligonucleotídeos antissenso contra il-34 e métodos de uso dos mesmos | |
| IL274363B2 (en) | Use of specific sirna against protein s for the treatment of hemophilia | |
| RU2016141263A (ru) | Аптамер для fgf2 и его применение | |
| WO2015188198A3 (en) | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta | |
| AR106543A1 (es) | Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético |